Endometrial Cancer Precision Diagnosis
At Fosun Health, endometrial cancer diagnosis is not just about “finding cancer”—it is about understanding the tumor’s molecular subtype and extent to design a plan that may preserve your uterus, your fertility, and your future. Our streamlined pathway delivers answers within days:
We use a multimodal approach tailored to the uterus and pelvis:
- Transvaginal Ultrasound (TVUS): Measures endometrial thickness and detects focal masses—the first-line screening tool.
- Saline Infusion Sonohysterography (SIS): Distends the uterine cavity to visualize polyps, fibroids, or endometrial lesions not seen on standard ultrasound.
- Contrast-Enhanced CT (Abdomen & Pelvis): Evaluates myometrial invasion, cervical involvement, lymph nodes, and distant metastases.
- Pelvic MRI: The most accurate tool for local staging—reveals depth of myometrial invasion, cervical stromal invasion, and lymph node involvement.
We obtain tissue with minimal discomfort:
- Office Endometrial Biopsy: A thin, flexible cannula is passed through the cervix to sample the endometrium—quick, safe, and definitive.
- Hysteroscopy with Directed Biopsy: For focal lesions or when office biopsy is inconclusive, a miniaturized camera visualizes the entire uterine cavity and targets the lesion precisely.
- PET-CT: Detects spread to pelvic/para-aortic lymph nodes, lungs, liver, or bones.
- Chest X-ray or CT: Rules out lung metastases.
Using NGS (Next-Generation Sequencing), we analyze the four molecular subtypes (POLE ultramutated, dMMR/MSI-H hypermutated, p53 mutant, and NSMP) as well as HER2 status, MSI/dMMR, TMB, NTRK fusions, and over 300 cancer-related genes. This determines whether your tumor will respond to immunotherapy (pembrolizumab for dMMR/MSI-H), anti-HER2 therapy (for HER2-positive serous carcinoma), hormone therapy, or targeted agents—ensuring your treatment is matched to your tumor’s unique biology, not a generic protocol.
